Drug intelligence / Profile preview

pentoxifylline + folic acid

Development stage: Preclinical
Lead developer: Silk Road Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

A combination drug consisting of pentoxifylline and folic acid. Pentoxifylline is a synthetic dimethylxanthine derivative that improves blood flow through blood vessels by exhibiting hemorheological, anti-oxidative, and anti-inflammatory properties. Folic acid is used to treat folic acid deficiency and various types of anemia. When combined, these medications appear to have a synergistic effect in patients with chronic kidney disease, particularly for delaying the initiation of hemodialysis in patients with advanced CKD who are on erythropoiesis-stimulating agent treatment.

Targets

PDE (Phosphodiesterase family)

Beyond the preview

Go deeper on pentoxifylline + folic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pentoxifylline + folic acid.

Explore the full profile